论文部分内容阅读
目的观察探讨氧气驱动雾化吸入博利康尼溶液和普米克令舒混悬液对于治疗小儿支气管哮喘的临床疗效,总结其临床经验。方法选取我院2010年3月至2012年3月98例小儿支气管哮喘的患儿,按照数字表随机抽取法分成2组,两组皆采用常规抗病毒和抗感染等综合治疗,对照组在常规治疗基础上给予常规超声雾化吸入治疗,观察组在常规治疗基础上给予氧气驱动雾化吸入博利康尼溶液和普米克令舒混悬液治疗,观察对比两组治疗效果。结果观察组临床症状治疗总有效率显著高于对照组(P<0.05),具有统计学意义。结论氧气驱动雾化吸入博利康尼溶液和普米克令舒混悬液对于治疗小儿支气管哮喘的临床疗效理想,且明显比常规超声雾化吸入效果好,能够有效地控制哮喘发作,加快病情转归,操作简便,具有重要的临床应用价值。
Objective To observe the clinical efficacy of aerosol-driven nebulized Boryconi solution and pulmicort suspension in the treatment of pediatric bronchial asthma, and summarize its clinical experience. Methods A total of 98 children with bronchial asthma in our hospital from March 2010 to March 2012 were randomly divided into two groups according to the digital table. Both groups were treated with routine antiviral and anti-infective methods. On the basis of the treatment, conventional ultrasonic atomization inhalation was given. In the observation group, oxygen-driven atomization inhalation of boryeucini and pulmicort resuspension were given on the basis of routine treatment. The therapeutic effect was observed and compared between the two groups. Results The total effective rate of clinical symptoms in observation group was significantly higher than that in control group (P <0.05), with statistical significance. Conclusions Oxygen-driven nebulization of bleomycin and pulmicort resuspension is good for the treatment of children with bronchial asthma, and its effect is better than that of conventional inhalation. It can effectively control the onset of asthma and accelerate the progression of the disease , Easy to operate, has important clinical value.